Scropolioside B inhibits IL-1 β and cytokines expression through NF- κ B and inflammasome NLRP3 pathways

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Zhu, Tiantian ^a   Zhang, Liuqiang ^a   Ling, Shuang ^a   Duan, Ju ^a   Qian, Fei ^a   Li, Yiming ^a   Xu, Jin Wen ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CARDIOLIPIN SYNTHETASE; CATALPOL; CRYOPYRIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 32; IRIDOID; MESSENGER RNA; SCROPOLIOSIDE B; SYNTHETASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARRIER PROTEIN; CRLS1 PROTEIN, HUMAN; INFLAMMASOME; MEMBRANE PROTEIN; NLRP3 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; EMBRYO; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; MATURATION; PROTEIN EXPRESSION; SCROPHULARIA DENTATA; SCROPHULARIACEAE; SIGNAL TRANSDUCTION; TIBETAN MEDICINE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHINESE MEDICINE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MONOCYTE;

ANTI-INFLAMMATORY AGENTS; CARRIER PROTEINS; CYTOKINES; GENE EXPRESSION; HEK293 CELLS; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; IRIDOID GLUCOSIDES; MEDICINE, CHINESE TRADITIONAL; MEMBRANE PROTEINS; MONOCYTES; NF-KAPPA B; SCROPHULARIA; SIGNAL TRANSDUCTION;

EID: 84908341637     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/819053     Document Type: Article

References (38)

1. Pawelec G., Goldeck D., Derhovanessian E., Inflammation, ageing and chronic disease. Current Opinion in Immunology 2014 29 1 23 28 10.1016/j.coi.2014.03.007 2-s2.0-84901044149
2. Coussens L. M., Zitvogel L., Palucka A. K., Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013 339 6117 286 291 10.1126/science.1232227 2-s2.0-84872445265
3. McKellar G. E., McCarey D. W., Sattar N., McInnes I. B., Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nature Reviews 2009 6 6 410 417 10.1038/nrcardio.2009.57 2-s2.0-69249222895
4. Perry V. H., Teeling J., Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Seminars in Immunopathology 2013 35 5 601 612 10.1007/s00281-013-0382-8 2-s2.0-84882571292
5. Schmitz M. L., Weber A., Roxlau T., Gaestel M., Kracht M., Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines. Biochimica et Biophysica Acta-Molecular Cell Research 2011 1813 12 2165 2175 10.1016/j.bbamcr.2011.06.019 2-s2.0-82555167069
6. Strowig T., Henao-Mejia J., Elinav E., Flavell R., Inflammasomes in health and disease. Nature 2012 481 7381 278 286 10.1038/nature10759 2-s2.0-84855989829
7. Duewell P., Kono H., Rayner K. J., Sirois C. M., Vladimer G., Bauernfeind F. G., Abela G. S., Franchi L., Nuñez G., Schnurr M., Espevik T., Lien E., Fitzgerald K. A., Rock K. L., Moore K. J., Wright S. D., Hornung V., Latz E., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010 464 1357 1361 10.1038/nature08938 2-s2.0-77955152608
8. Schroder K., Zhou R., Tschopp J., The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010 327 5963 296 300 10.1126/science.1184003 2-s2.0-74549184092
9. Masters S. L., Dunne A., Subramanian S. L., Hull R. L., Tannahill G. M., Sharp F. A., Becker C., Franchi L., Yoshihara E., Chen Z., Mullooly N., Mielke L. A., Harris J., Coll R. C., Mills K. H. G., Mok K. H., Newsholme P., Nuñez G., Yodoi J., Kahn S. E., Lavelle E. C., O'Neill L. A. J., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 β 2 in type 2 diabetes. Nature Immunology 2010 11 10 897 904 10.1038/ni.1935 2-s2.0-77956958947
10. Petrasek J., Bala S., Csak T., Lippai D., Kodys K., Menashy V., Barrieau M., Min S.-Y., Kurt-Jones E. A., Szabo G., IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. Journal of Clinical Investigation 2012 122 10 3476 3489 10.1172/JCI60777 2-s2.0-84867176929
11. Dupaul-Chicoine J., Yeretssian G., Doiron K., Bergstrom K. S. B., McIntire C. R., LeBlanc P. M., Meunier C., Turbide C., Gros P., Beauchemin N., Vallance B. A., Saleh M., Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010 32 3 367 378 10.1016/j.immuni.2010.02.012 2-s2.0-77949965210
12. Sidiropoulos P. I., Goulielmos G., Voloudakis G. K., Petraki E., Boumpas D. T., Inflammasomes and rheumatic diseases: evolving concepts. Annals of the Rheumatic Diseases 2008 67 10 1382 1389 10.1136/ard.2007.078014 2-s2.0-53149123653
13. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006 440 7081 237 241 10.1038/nature04516 2-s2.0-32944468985
14. Latz E., Xiao T. S., Stutz A., Activation and regulation of the inflammasomes. Nature Reviews Immunology 2013 13 6 397 411 10.1038/nri3452 2-s2.0-84878237993
15. Zhang L.-Q., Li Y.-M., Advances in studies on chemical constituents in plants of Scrophularia L. and their pharmacological effects in recent ten years Chinese Traditional and Herbal Drugs 2011 42 11 2360 2368 2-s2.0-82855181992
16. Viljoen A., Mncwangi N., Vermaak I., Anti-inflammatory iridoids of botanical origin. Current Medicinal Chemistry 2012 19 14 2104 2127 2-s2.0-84860662131
17. Tundis R., Loizzo M. R., Menichini F., Statti G. A., Biological and pharmacological activities of iridoids: recent developments. Mini-Reviews in Medicinal Chemistry 2008 8 4 399 420 10.2174/138955708783955926 2-s2.0-42949138079
18. Bas E., Recio M. C., Máñez S., Giner R. M., Escandell J. M., López-Ginés C., Ríos J.-L., New insight into the inhibition of the inflammatory response to experimental delayed-type hypersensitivity reactions in mice by scropolioside A. European Journal of Pharmacology 2007 555 2-3 199 210 10.1016/j.ejphar.2006.10.012 2-s2.0-33846022296
19. Ahmed B., Al-Rehaily A. J., Al-Howiriny T. A., El-Sayed K. A., Ahmad M. S., Scropolioside-D2 and harpagoside-B: two new iridoid glycosides from Scrophularia deserti and their antidiabetic and antiinflammatory activity. Biological and Pharmaceutical Bulletin 2003 26 4 462 467 10.1248/bpb.26.462 2-s2.0-0642286449
20. Stavri M., Mathew K. T., Gibbons S., Antimicrobial constituents of Scrophularia deserti. Phytochemistry 2006 67 14 1530 1533 10.1016/j.phytochem.2006.05.011 2-s2.0-33746208951
21. Benito P. B., Lanza A. M. D., Sen A. M. S., De Santos Galindez J., Matellano L. F., Gómez A. S., Martínez M. J. A., Effects of some iridoids from plant origin on arachidonic acid metabolism in cellular systems. Planta Medica 2000 66 4 324 328 10.1055/s-2000-8549 2-s2.0-0034039525
22. Wang P., Sun L., Tan J., Xu J., Guo F., Li Y., Two new glycosidated coumaramides from Clerodendron cyrtophyllum. Fitoterapia 2012 83 8 1494 1499 10.1016/j.fitote.2012.08.016 2-s2.0-84870842728
23. Zhang L., Feng L., Jia Q., Xu J., Wang R., Wang Z., Wu Y., Li Y., Effects of β -glucosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. Bioorganic and Medicinal Chemistry 2011 19 16 4882 4886 10.1016/j.bmc.2011.06.069 2-s2.0-79961167887
24. Park K. S., Kim B. H., Chang I.-M., Inhibitory potencies of several iridoids on cyclooxygenase-1, cyclooxygnase-2 enzymes activities, tumor necrosis factor- and nitric oxide production In Vitro. Evidence-based Complementary and Alternative Medicine 2010 7 1 41 45 10.1093/ecam/nem129 2-s2.0-77249176587
25. Choi H.-J., Jang H.-J., Chung T.-W., Jeong S.-I., Cha J., Choi J.-Y., Han C. W., Jang Y.-S., Joo M., Jeong H.-S., Ha K.-T., Catalpol suppresses advanced glycation end-products-induced inflammatory responses through inhibition of reactive oxygen species in human monocytic THP-1 cells. Fitoterapia 2013 86 1 19 28 10.1016/j.fitote.2013.01.014 2-s2.0-84876364069
26. Nold-Petry C. A., Nold M. F., Zepp J. A., Kim S.-H., Voelkel N. F., Dinarello C. A., IL-32-dependent effects of IL-1 β on endothelial cell functions. Proceedings of the National Academy of Sciences of the United States of America 2009 106 10 3883 3888 10.1073/pnas.0813334106 2-s2.0-62649165849
27. Rathinam V. A. K., Vanaja S. K., Fitzgerald K. A., Regulation of inflammasome signaling. Nature Immunology 2012 13 4 333 342 10.1038/ni.2237 2-s2.0-84858688293
28. Iyer S. S., He Q., Janczy J. R., Elliott E., Zhong Z., Olivier A., Sadler J., Knepper-Adrian V., Han R., Qiao L., Eisenbarth S., Nauseef W., Cassel S., Sutterwala F., Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 2013 39 2 311 323 10.1016/j.immuni.2013.08.001 2-s2.0-84882614243
29. Dinarello C. A., A clinical perspective of IL-1 β as the gatekeeper of inflammation. European Journal of Immunology 2011 41 5 1203 1217 10.1002/eji.201141550 2-s2.0-79955148909
30. Joosten L. A. B., Netea M. G., Kim S.-H., Yoon D.-Y., Oppers-Walgreen B., Radstake T. R. D., Barrera P., Van De Loo F. A. J., Dinarello C. A., Van Den Berg W. B., IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America 2006 103 9 3298 3303 10.1073/pnas.0511233103 2-s2.0-33644765841
31. Heinhuis B., Koenders M. I., Van De Loo F. A., Netea M. G., Van Den Berg W. B., Joosten L. A. B., Inflammation-dependent secretion and splicing of IL-32 γ in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America 2011 108 12 4962 4967 10.1073/pnas.1016005108 2-s2.0-79953197232
32. Kim Y.-G., Lee C.-K., Kim S.-H., Cho W.-S., Mun S. H., Yoo B., Interleukin-32 γ enhances the production of IL-6 and IL-8 in fibroblast-like synoviocytes Via Erk1/2 activation. Journal of Clinical Immunology 2010 30 2 260 267 10.1007/s10875-009-9360-2 2-s2.0-77953536536
33. Moschen A. R., Fritz T., Clouston A. D., Rebhan I., Bauhofer O., Barrie H. D., Powell E. E., Kim S.-H., Dinarello C. A., Bartenschlager R., Jonsson J. R., Tilg H., Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology 2011 53 6 1819 1829 10.1002/hep.24285 2-s2.0-79957525893
34. Xu Q., Pan X., Shu X., Cao H., Li X., Zhang K., Lu J., Zou Y., Liu H., Zhang Y., Yang D., Ning Q., Shen G., Li G., Increased interleukin-32 expression in chronic hepatitis B virus-infected liver. Journal of Infection 2012 65 4 336 342 10.1016/j.jinf.2012.05.009 2-s2.0-84865990848
35. Kim S.-H., Han S.-Y., Azam T., Yoon D.-Y., Dinarello C. A., Interleukin-32: a cytokine and inducer of TNF Immunity 2005 22 1 131 142 10.1016/j.immuni.2004.12.003 2-s2.0-12444304581
36. Nold-Petry C. A., Rudloff I., Baumer Y., Ruvo M., Marasco D., Botti P., Farkas L., Cho S. X., Zepp J. A., Azam T., Dinkel H., Palmer B. E., Boisvert W. A., Cool C. D., Taraseviciene-Stewart L., Heinhuis B., Joosten L. A. B., Dinarello C. A., Voelkel N. F., Nold M. F., IL-32 promotes angiogenesis. Journal of Immunology 2014 192 2 589 602 10.4049/jimmunol.1202802 2-s2.0-84892700407
37. Kobayashi H., Huang J., Ye F., Shyr Y., Blackwell T. S., Lin P. C., Interleukin-32 β propagates vascular inflammation and exacerbates sepsis in a mouse model. PLoS ONE 2010 5 3 e9458 10.1371/journal.pone.0009458 2-s2.0-77949740315
38. Heinhuis B., Popa C. D., van Tits B. L. J. H., Kim S.-H., Zeeuwen P. L., van den Berg W. B., van der Meer J. W. M., van der Vliet J. A., Stalenhoef A. F. H., Dinarello C. A., Netea M. G., Joosten L. A. B., Towards a role of interleukin-32 in atherosclerosis. Cytokine 2013 64 1 433 440 10.1016/j.cyto.2013.05.002 2-s2.0-84883556030